一项评估水凝胶在宫颈癌近距离放疗中降低直肠剂量应用的I期临床试验
这项前瞻性I期临床研究纳入8例中国宫颈癌患者,在完成50.4 Gy/28次调强放疗后,经CT引导经阴道后穹窿注射10 mL水凝胶,再行CT或MRI引导的影像引导近距离放疗,高危临床靶区目标剂量为6 Gy分5次。结果显示水凝胶可有效增大宫颈与直肠间距、限制直肠剂量,短期未观察到严重不良事件,但需进一步研究确认长期安全性和有效性。
要点
- 8例宫颈癌患者经阴道后穹窿注射10 mL水凝胶后,宫颈与直肠间距显著增大。
- 近距离放疗中直肠D2cc平均为60.9 ± 3.4 Gy,未出现3级及以上急性毒性反应。
- 无水凝胶相关不良事件,主观生活质量评分注射前后无显著变化。
核心结论
- 水凝胶应用有效增大了宫颈癌近距离放疗中宫颈与直肠的间距,限制了直肠剂量且未增加其他危及器官剂量。
- 短期内未观察到严重不良事件,表明该方法安全可靠。
- 需进一步研究确认其长期安全性和有效性。
研究设计与样本
- 前瞻性I期临床研究,纳入8例中国宫颈癌患者。
- 完成50.4 Gy/28次调强放疗后,经CT引导经阴道后穹窿注射10 mL水凝胶。
- 行CT或MRI引导的影像引导近距离放疗,高危临床靶区目标剂量为6 Gy分5次。
- 记录每次近距离放疗的直肠、乙状结肠和膀胱D2cm3,MRI测量直肠与宫颈或肿瘤间距及间隔凝胶体积。
- 记录QLQ-C30和QLQ-CX24评分评估治疗结局,并记录所有不良事件。
主要发现
- 8例患者中,直肠D2cc平均为60.9 ± 3.4 Gy,乙状结肠为64.7 ± 6.8 Gy,膀胱为77.1 ± 7.4 Gy。
- 凝胶注射后宫颈与直肠间距显著增大。
- 8例患者近距离放疗期间均未发生3级及以上急性毒性反应,无患者发生晚期直肠毒性。
- 未观察到明确与水凝胶相关的不良事件,患者主观生活质量评分在凝胶注射前后无显著变化。
- 注射后24至36周观察到水凝胶体积缩小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究确认其长期安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study represents a prospective phase I clinical research to verify the effectiveness and reliability of hydrogel application in Chinese cervical cancer patients. MATERIALS AND METHODS: Eight patients were enrolled in the study. After completing intensity-modulated radiotherapy at 50.4 Gy/28 fractions, a 10 mL injection of hydrogel was administered to each patient through the posterior vaginal fornix under CT-guidance. Image-guided brachytherapy under CT or MRI guidance was given with a target dose of 6 Gy in 5 fractions to the high-risk clinical target volume. Rectal, sigmoid colon, and bladder D2cm3 were recorded for each brachytherapy. MRI scans were performed to measure the distance between the rectum and the cervix or tumor, as well as the spacer gel volume. Patients' QLQ-C30 and QLQ-CX24 scores were recorded to assess treatment outcomes, and all adverse events were documented. RESULTS: Among the eight patients, the average D2cc was 60.9 ± 3.4 Gy for the rectum, 64.7 ± 6.8 Gy for sigmoid colon and 77.1 ± 7.4 Gy for bladder, respectively. The distance between the cervix and rectum significantly increased after gel injection. None of the eight patients experienced grade 3 or higher acute toxic reactions during brachytherapy. None patient experienced late rectal toxicity. No adverse events definitively associated with the hydrogel were observed. Patients' subjective quality of life scores did not significantly change before and after gel injection. The reduction ro the volume of the hydrogel were observed during the 24 to 36 weeks after injection. CONCLUSION: The application of the hydrogel effectively increased the distance between the cervix and rectum in brachytherapy for cervical cancer, limiting the rectal dose without increasing doses to other critical organs. In the short term, no severe adverse events were observed, indicating the safety and reliability of this approach. Further research is warranted to confirm its long-term safety and effectiveness.
引用
- Wang Y, Zhen H, Hu K, et al. A phase I clinical trial evaluating the application of hydrogel in reducing rectal dose during cervical cancer brachytherapy. Clin Transl Radiat Oncol. 2024. PMID: 39386060. doi:10.1016/j.ctro.2024.100867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。